Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Lines Up $1 Billion For China R&D

This article was originally published in PharmAsia News

Executive Summary

Novartis announced Nov. 3 a five-year, $1 billion investment in China, upping the ante for multinationals trying to build strong foundations in China's burgeoning R&D space

You may also be interested in...



Novartis Replaces China President With Hewlett-Packard VP For Government Affairs, Gearing Up For Growth

To drive China growth, the Swiss pharma giant announced a change in leadership in China as former Wyeth/Pfizer government affairs expert, Ms. Xu Haiying takes reigns as new China president.

After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod

Novartis looks to take on Merck’s Januvia in China, noting it will have a level-playing field despite playing catch up in the market with the world’s largest diabetes population.

After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod

Novartis looks to take on Merck’s Januvia in China, noting it will have a level-playing field despite playing catch up in the market with the world’s largest diabetes population.

Related Content

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel